Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%.

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna fell to a new 52-week low after some disappointing news. The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has ...

Moderna’s stock price has dropped about 60% in the past 12 months. Facing this set of challenges, Moderna in September laid out a plan to cut annual R&D spending by more than 20%, or $1.1 ...

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...

Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024 ...

Plexi Images / GHI / UCG / Universal Images Group via Getty Images Moderna shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S ...

As for 2024, Moderna says it reeled in sales between $3 billion and $3.1 billion, a result that came in at the low end of the company’s previous guidance range of $3 billion to $3.5 billion.